Avanir Pharmaceuticals has announced the launch of Onzetra Xsail sumatriptan nasal powder in the US. The FDA approved Onzetra Xsail for the treatment of migraine in adult patients in January 2016.
Avanir President and CEO Rohan Palekar commented, “Making our second product available to patients is an important milestone for Avanir. The launch of Onzetra is further evidence of our commitment to bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.”
The company said that it “provides patient support services, including a reimbursement counseling hotline to help people who suffer from migraines navigate potential administrative insurance issues and a co-pay assistance program to reduce out-of-pocket costs for eligible patients.”
Read the Avanir press release.
